ClinicalTrials.gg
RecruitingNCT05698576TPF-LITTUpdated Jan 26, 2023

TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer

An interventional study of TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT) in Prostate Cancer, Adverse Effects Surgery and MRI, sponsored by Urological Research Network, LLC. Recruiting at 1 site in United States. Open to male participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Urological Research Network, LLC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2023, 3 years 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
2,250th of 3,024
20 · median 48
Started
2022
with 120 others
No phase
764 of 3,597
157 open now
Primary completion
2023-01
later than 36 of 968 live
Registered
2,833rd of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 2,250th largest by planned enrollment of the 3,024 interventional ones that give a count, is one of 121 that started in 2022, is one of 764 with no phase, reaches primary completion later than 36 of the 968 other live ones, and was the 2,833rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 50 Years to 80 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is set up as a phase I prospective, single center, device interventional pilot study carried in office setting under local anesthesia. It will assess the tolerance and safety of target fusion ablation of prostate cancer tumors using Laser Induced Thermal Therapy (TFA-LITT) guided by fusion imaging in men 50 to 80 years of age with low to intermediate risk prostate cancer

Prostate Cancer is currently managed with in a discrete fashion where patients either enroll in active surveillance protocols (No intervention) or undergo full intervention via whole gland treatments - most commonly radical surgery or radiation. These treatments have not shown definitive gains in all cause survival and not uncommonly harbor undesirable adverse effects, most notably: impotency and incontinence. Such events elicit significant and noticeable changes on a male lifestyle and for most prostate cancer tumors are considered overtreatment. This study aims to evaluate the use of TFA-LITT in the office setting under local anesthesia - greatly decreasing patient perioperative surgical risk - focused on the organ sparing cancer lesion ablation, where organ function is preserved.

The fundamental objective is to determine the tolerance and safety of TFA-LITT in men with low to intermediate risk prostate cancer, successful performed in the outpatient office-based setting under local anesthesia directed by fusion imaging. Secondary objectives include: 1-Biopsy proven cancer control of ablated areas 12 months after procedure; 2-Uroflowmetry and urinary function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 3- Sexual function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 4- MRI changes of ablated area one, three and 12 months after TFA-LITT; 5- Absence or presence of ejaculation after TFA-LITT.

Read the detailed description

The field of urology currently demands better options for men diagnosed with prostate cancer, the most common solid tumor in the US and Western Europe. Recently, active surveillance has become a main alternative for patients and physicians seeking to avoid the overtreatment phenomenon associated with standard treatments. However, most men on surveillance protocols for prostate cancer end up converting to "definitive" management whether surgery or radiation within 5 years from diagnosis.

The TRANBERG®\|Thermal Therapy System (Clinical Laserthermia Systems AB. Scheelevägen 2 \| 223 81 Lund, Sweden), is a 25 W, 1064 nm diode laser. It uses a disposable laser applicator 14G that allows the insertion of a laser applicator (15G) with a fiberoptic core of 550µm. This thermal therapy laser system is indicated for minimal invasive ablation procedures so called Laser Induced Thermal Therapy (LITT) or also called Laser Ablation for prostate treatments. During LITT, light causes damage in tissue due to absorption of light and through heat conduction into the tissue of the absorbed energy. Light tissue interaction is reliable, reproducible, and safe. The laser fiber tip induces necrosis near the tip and coagulative effects deeper in tissues through heat conduction. The body cleans up treated tissue over time. Much experience is gained with laser ablation in different organs.

The development of medical fusion devices that incorporate the precise diagnostic findings from MRI with the flexibility of ultrasound has expanded the precision of prostate biopsies and has led thinking into the current management of prostate cancer, opening for consideration the case for partial gland ablation as an option with fewer side effects.12 Conceivably, the most promising role of fusion imaging would be in the management spectrum of prostate cancer. MRI/US fusion imaging has tremendous advantages, it delivers precise anatomical boundaries and perspectives to surgeons as they sought to destroy cancer lesions and spare healthy tissue. A better understanding on their role in ablation treatments is imperative.

The Focalyx® Fusion (Focalyx, 2140 West 68th St, #204a. Miami Lakes, FL, USA) is a novel disruptive medical device that enables an office based transperineal approach to be conducted using real-time fusion. The characteristics of this fusion device and trials studies have been well documented. This theoretically makes available a safe and laser fiber energy delivery that results in expedient and short procedure times. The Focalyx® Fusion has been used safely in the transperineal diagnosis (fusion biopsies) and management (fusion targeted cryoablation) of men with Prostate Cancer in the office setting. However, targeted prostate cryoablation carries some intrinsic disadvantages as it requires high pressure gasses. Argon and helium are not readily available worldwide, and its efficacy depends on several timely cycles demanding procedure times of about an hour or more. LITT can be accomplished in efficient minutes treatment times and can address the multi-focality of prostate cancer quite effectively. Laser ablation has proven effective when conducted in an MRI bore, however, the immensity of these machines, limited size of the bore, prone positioning and constant in and out verification makes this approach not practical. Fusion laser ablation for prostate cancer is a novel concept that can bring together the precision of MRI with the practicality of ultrasound.

The combination of the TRANBERG® laser and the FOCALYX® Fusion medical device will allow us to perform targeted transperineal fusion laser induced thermal therapy (TPF-LITT) of prostate cancer lesions. This approach portends significant advantages that the investigators can consider, among them: lesion directed ablation, sparring of critical organs and structures such as the bladder neck, NVB, urethral sphincter and rectum. Moreover, healthy tissue is spared and can perform its function, if it mirrors what the investigators have accomplished with target fusion cryoablation. It shall be expected that most men will have preservation of some ejaculation, mild changes in sexual function and no incontinence following treatment with TPF-LITT. In fact, from a urinary function status, the investigators expect patients to suffer no harm either subjectively or objectively. However, all these thoughts require rigorous evaluation. Today, there is no data or evaluation of its safety profile if/when conducted in an office setting under local anesthesia. Therefore, in this study, the principal aim is to assess tolerability and safety profile of TRANBERG® TPF-LITT conducted in men with Prostate Cancer in the office setting.

Objective: The primary objective of this study is to assess tolerability and safety, of TRANBERG® TPF-LITT in Prostate Cancer patients with clinically localized disease. The secondary objectives are to evaluate clinical performance, changes in erectile and sexual function as well as imaging volumetric changes in prostate lesions, prostate size as well as cancer control in treated areas Study design: This study is set up as open label, prospective, single center, interventional study.

Study population: Patients with low or intermediate risk prostate cancer ≥ 50 years of age.

Study Intervention: Upon meeting inclusion and exclusion criteria, subjects will undergo prostate ablation planning where the ablation areas will be noted irrespective of location so long, they are confined to this organ. The planning will allow to spare, if possible, critical structures such as the urethra, neurovascular bundles, and bladder neck. TRANBERG® TPF-LITT treatment execution will be conducted under local anesthesia using the FOCALYX® Fusion medical device as guidance for precise laser fiber localization and real-time monitoring. This investigation will employ a single fiber that will be repositioned to destroy several targeted areas to achieve the TFP-LITT goals. The surgeon will deliver the laser energy and adjust if needed. The areas treated will develop coagulative necrosis with scarring as a response to TPF-LITT. Upon conclusion of the procedure, the patient will have a multiparametric MRI of the prostate to determine the extent of ablation with this powerful technology immediately after treatment, and subsequently 1, 3 and 12 months after.

Main study parameters/endpoints: Tolerability and safety represents the main endpoints of this trial. Tolerability will be assessed during the execution of TFP-LITT. Patients will be provided with a pain analog scale and pain scores will be recorded before initiation of the procedure and during several milestones of the procedure. A final overall pain assessment will be recorded as well. Safety will be assessed during the 7-day, 30-day and 90-day clinic visits. Adverse events (AEs) will be monitored and reported using the CTCAE scale, as perioperative assessments will be conducted at each of these milestones. A grade 3 or worse AEs based on the CTCAE v5.0 within 90 days post procedure will be considered severe. Secondary outcomes will include cancer control, urinary and sexual functional outcomes. Cancer control will be measured with MRI at several milestones, serum PSA changes during the year and the definitive measure will be a Transperineal MR/US Fusion Biopsy at one year of follow up. Urinary and Sexual functional outcomes will be determined by evaluating changes in the validated questionnaires. Ejaculation will be monitored by direct questions.

The investigators aim to streamline the follow up focusing on safety according to standard of care. Patients will be instructed to contact us if they perceive any AEs. The principal investigator will oversee each patient for any AEs. Patients will be followed up in the clinic 7 days post procedure for catheter removal and AEs assessments. They will be contacted 30 days after the procedure and an AEs questionnaire will be administered as well. AEs, IPSS and SHIM assessments will be done at the 6 weeks and 3-month visits. IPSS and SHIM assessments will be done at the 6-month, 9-months and 12-months visits. Flow and volumetric studies will be conducted 3 months and 12 months from procedure date. From an oncological perspective, patients will have serum markers evaluations - PSA, Testosterone Creatinine and GFR measurements prior to a multiparametric MRI and subsequently before each MRI at months 1, 3 and 12 after TPF-LITT procedure. Critically, the Focalyx® Fusion device will be used to assess the delta changes for each lesion and overall change in prostate configuration after each MRI performed. This will allow further understanding of the speed of tissue retraction, remodeling, and spatial orientation of the treated areas for each patient. Finally at 12 months, a MR/US Transperineal fusion biopsy will be performed to assess the ablated tissue cancer sterility.

In Conclusion, TRANBERG® TPF-LITT will expose patients to potential intervention risks. However, it is our estimation and bias these potential risks will be favorable or equal to those observed with compared available standard minimal invasive treatment approaches such as active surveillance. The risks usually associated with transrectal procedures is eliminated as all treatments will performed via a transperineal access. The burden is in our opinion favorable and acceptable.

03

Conditions studied

  • Prostate Cancer
  • Adverse Effects Surgery
  • MRI
  • Ultrasound
  • Sexual Function Disturbances
  • Urinary Incontinence
  • Urinary Function Disorders
  • Prostate Biopsy
  • Ablation
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to sign
  • Subject is able and willing to complete all procedure and follow-up visits indicated in the protocol
  • Absence of urinary retention
  • Prostate volume: ≥ 18 and ≤ 100 cc, measured by transrectal ultrasound
  • Serum creatinine levels \<2 ng/dl and > 45
  • Serum PSA levels \< 20 ng/ml
  • Multiparametric prostate MRI with piRADS scores 3-5
  • Prostate volume: ≥ 18 and ≤ 100 cc, measured by MRI
  • Presence of Intermediate risk prostate cancer with a volume that is less than 1/3 of the gland volume by MRI evaluation

Exclusion criteria

Exclusion Criteria:

  • Post-void residual (PVR): > 250 mL or > 50% of voided volume
  • Previous prostate cancer intervention (Radiation therapy, brachytherapy, prostate cryoablation
  • Major neurological conditions such as Alzheimer's, Parkinson, Multiple sclerosis, ALS, spinal cord injury
  • Evidence of neurogenic bladder determined by urodynamics studies
  • Presence of Indwelling Foley catheter or on active regime of clean intermittent catheterization (CIC) in the prior 30 days
  • Active urinary tract infection determined by urinary cultures
  • SHIM score \<14
  • IPSS score >23
  • Acute prostatitis
  • Macroscopic hematuria without a known contributing factor
  • History of colorectal carcinoma with anterior perineal resection of rectum
  • History of pelvic radiation therapy or radical pelvic surgery
  • History of bladder neck contracture and/or urethral strictures within the 5 years prior to the date
  • Bladder stones
  • Medical for undergoing TPFLA surgery (eg, infection, coagulopathy, significant cardiac or other medical risk factors for surgery)
  • Diagnosed or suspected bleeding or coagulopathic disorder such as hemophilia, ITP, TTP
  • Medical contraindication to being subjected to local anesthesia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    TPF-LITT ARM

    partial gland ablation of the prostate using laser device and imaging fusion

    Device: TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT)

Interventions

  • DeviceTRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT)

    A perineal local anesthesia block is performed with patient on lithotomy. The ultrasound probe is advanced, secured to digital stepper. The live ultrasound image feed is visible on the FOCALYX® Fusion device. Image co-registration (MR/US) will be performed. The FOCALYX® Fusion device shows outline of the prostate on the MRI and the target area(s) in real-time. The urologist advances laser fiber introducer, temperature probes to indicated coordinates. Target treatment - applying TRANBERG® laser energy over the treatment area and controlling delivery with a pedal. Treatment is monitored using FOCALYX® Fusion device in real-time. One laser fiber will be used and a single or multiple applications may be required. The fiber will be relocated to other targets if present. Patient will be dismissed to the MRI center where a multiparametric MRI will be conducted. After this study is completed, the patient will be discharged home with instructions and contact information.

    Also known as: Fusion Imaging Laser induced thermal therapy for prostate partial gland ablation.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of TRANBERG® TPF-LITT performed in the office setting under local anesthesia.

    Tolerability will be assessed during the execution of TFP-LITT at several phases of the treatment. An analog pain scale will be provided to the patient, whom will be asked to describe any pain scores at each of the following treatment successions: 1. superficial perineal block, 2. foley advancement, 3. deep perineal block, 4. fusion co-registration, 5. before and after each ablation, 6-Once the patient has recovered, he will be asked for an overall pain assessment. Safety will be evaluated by assessments of the 7-day, 30-day and 90-day AEs reported using the CTCAE scale, as perioperative assessments will be conducted at each of these milestones. A grade 3 or worse AEs based on the CTCAE v5.0 within 90 days post procedure will be considered severe. Any registered AEs will be labelled as follows: 1. Not related 2. Possible 3. Probable 4. Causal relationship

    Time frame: 90 days

Secondary outcomes

  1. Average Ablated area volume (in cc) measured by MRI immediately following the procedure

    patients will undergo a multiparametric MRI immediately after the procedure and the ablated areas will be contoured and the dimensions on cubic centimeters will be recorded as ablation area

    Time frame: 24-72 hours after procedure

  2. Average Ablated area volume (in cc) measured by MRI 1-month following the procedure

    patients will undergo a multiparametric MRI 30 days (1-month) after the procedure and the ablated areas will be contoured and the dimensions on cubic centimeters will be recorded as ablation area

    Time frame: 30 days

  3. Average Ablated area volume (in cc) measured by MRI 3-month following the procedure

    patients will undergo a multiparametric MRI 90 days (3-month) after the procedure and the ablated areas will be contoured and the dimensions on cubic centimeters will be recorded as ablation area

    Time frame: 90 days

  4. Average Ablated area volume (in cc) measured by MRI 1-year following the procedure

    patients will undergo a multiparametric MRI 1-year after the procedure and the ablated areas will be contoured and the dimensions on cubic centimeters will be recorded as ablation area

    Time frame: 1 year

  5. Number of patients with a 75% decrease in Serum PSA levels (ng/ml) after procedure measured at fixed intervals

    The PSA will be obtained as well at 1, 3, 6, 9 and 12-months post procedure.

    Time frame: 1 year

  6. Number of patients with presence of cancer cells in treated -ablated- area

    pathological assessment of samples obtained trough a MR/US Transperineal Fusion biopsy of the prostate treated area

    Time frame: 1 year

  7. Number of patients with a 50% increase in qMAX measured in cc/second on flow studies

    Uroflowmetry in cc/s will be performed on patients at 3 and 12 months after the procedure. Assessment of maximal flow rate -qmax (cc/seconds) will be obtained

    Time frame: 12 Months

  8. Number of patients with a 7 point drop in the International Prostate Symptom Score (IPSS)

    Patients will be asked to answer the validated questionnaire - international prostate symptom scores (IPSS) - at 1,3 ,6 ,9 and 12 months following the procedure The IPSS scores range from 1 to 35

    Time frame: 12 Months

  9. Number of patients with a 5 point drop in the sexual health inventory for men (SHIM) scores

    Patients will be asked to answer the validated questionnaire - sexual health inventory for men (SHIM) - at 1,3 ,6 ,9 and 12 months following the procedure The SHIM scores range from 1 to 25

    Time frame: 12 Months

  10. Number of men with absent ejaculation

    Assessed by a direct yes or no answer to the question at 1,3 ,6 ,9 and 12 months following the procedure

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
  • Urology Specialist Group
    Hialeah, Florida 33016, United States
    Recruiting
08

References and documents

Publications

  • Carter G, Clover K, Britton B, Mitchell AJ, White M, McLeod N, Denham J, Lambert SD. Wellbeing during Active Surveillance for localised prostate cancer: a systematic review of psychological morbidity and quality of life. Cancer Treat Rev. 2015 Jan;41(1):46-60. doi: 10.1016/j.ctrv.2014.11.001. Epub 2014 Nov 13. PubMed 25467109 ↗
  • Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20;29(27):3669-76. doi: 10.1200/JCO.2011.34.9738. Epub 2011 Aug 8. PubMed 21825257 ↗
  • Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14. PubMed 27626136 ↗
  • Loeb S, Carter HB, Schwartz M, Fagerlin A, Braithwaite RS, Lepor H. Heterogeneity in active surveillance protocols worldwide. Rev Urol. 2014;16(4):202-3. No abstract available. PubMed 25548550 ↗
  • Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ; Collaborators. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol. 2021 Nov;206(5):1147-1156. doi: 10.1097/JU.0000000000001937. Epub 2021 Sep 10. PubMed 34503355 ↗
  • Al-Hakeem Y, Raz O, Gacs Z, Maclean F, Varol C. Magnetic resonance image-guided focal laser ablation in clinically localized prostate cancer: safety and efficacy. ANZ J Surg. 2019 Dec;89(12):1610-1614. doi: 10.1111/ans.15526. Epub 2019 Nov 3. PubMed 31679182 ↗
  • Lee T, Mendhiratta N, Sperling D, Lepor H. Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Rev Urol. 2014;16(2):55-66. PubMed 25009445 ↗
  • Walser E, Nance A, Ynalvez L, Yong S, Aoughsten JS, Eyzaguirre EJ, Williams SB. Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease. J Vasc Interv Radiol. 2019 Mar;30(3):401-409.e2. doi: 10.1016/j.jvir.2018.09.016. PubMed 30819483 ↗
  • Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18. PubMed 29552975 ↗
  • Simmons LAM, Kanthabalan A, Arya M, Briggs T, Barratt D, Charman SC, Freeman A, Gelister J, Hawkes D, Hu Y, Jameson C, McCartan N, Moore CM, Punwani S, Ramachandran N, van der Meulen J, Emberton M, Ahmed HU. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. Br J Cancer. 2017 Apr 25;116(9):1159-1165. doi: 10.1038/bjc.2017.57. Epub 2017 Mar 28. PubMed 28350785 ↗
  • Bianco FJ, Martinez-Salamanca JI. Focalyx Dx, Bx, Tx et Apps: A novel contemporary fusion paradigm for the management of prostate cancer. Arch Esp Urol. 2016 Jul;69(6):353-63. PubMed 27416639 ↗
  • Hu Y, van den Boom R, Carter T, Taylor Z, Hawkes D, Ahmed HU, Emberton M, Allen C, Barratt D. A comparison of the accuracy of statistical models of prostate motion trained using data from biomechanical simulations. Prog Biophys Mol Biol. 2010 Dec;103(2-3):262-72. doi: 10.1016/j.pbiomolbio.2010.09.009. Epub 2010 Sep 30. PubMed 20869389 ↗

Individual participant data

Plan to share: Yes — De-Identified datasets may be shared for Meta-Analysis purposes or Matched cohort analysis

Supporting information: Clinical study report

Time frame: 3 years

Access criteria: formal request, institutional agreements

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jan 2023, 10 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 10 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Jan 26, 2023
StartActual
Mar 16, 2022
Primary completionEst.
Jan 27, 2023
CompletionEst.
Jan 30, 2033
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05698576
Lead sponsor
Urological Research Network, LLC
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Mar 16, 2022
Primary completion
Jan 27, 2023 (estimated)
Completion
Jan 30, 2033 (estimated)
Last update
Jan 26, 2023

Study contacts

Cielo D Guerra, BS
Contact
cielo@besturology.net
786-431-2014
Luanda Perez, PA.C
Contact
luanda@besturology.net
305-822-7227
Fernando J Bianco, MD
principal investigator · Urological Research Network
Isabel H Lopez, BS., MBA
study director · Urological Research Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion